Proteomic Landscapes of 3D and 2D Ovarian Cancer Models: Insights into Carboplatin Response

Study Background and Research Question

High-grade serous ovarian carcinoma (HGSOC) remains the deadliest gynecological malignancy, with over 300,000 diagnoses and more than 200,000 deaths worldwide annually. Most patients present at an advanced, metastatic stage, and durable cures are rare. Although immunotherapies and targeted agents are in development, platinum-based DNA synthesis inhibitors like carboplatin remain the core agents in both clinical and preclinical research (reference study). However, most drug discovery efforts depend on two-dimensional (2D) monolayer cultures, which poorly recapitulate the complex in vivo microenvironment, especially cell–cell and cell–extracellular matrix interactions. This raises critical questions: How do 3D spheroid models, which better mimic in vivo conditions, alter the proteome of HGSOC cells? And do these changes influence carboplatin sensitivity or resistance?

Key Innovation from the Reference Study

The reference paper provides the first quantitative whole-cell proteomics comparison of four HGSOC cell lines cultured in both 2D monolayers and 3D spheroids. By employing isobaric labeling and mass spectrometry, the authors mapped over 6,400 proteins and identified 371 that were significantly and consistently altered between the two culture conditions. Crucially, the study interrogates how these dimensionality-driven proteomic changes modulate resistance to carboplatin, a platinum-based DNA synthesis inhibitor widely used in preclinical oncology research. This work not only expands our molecular understanding of in vitro cancer models but also pinpoints candidate proteins and pathways that could be targeted to overcome platinum resistance (full article).

Methods and Experimental Design Insights

Four HGSOC cell lines were selected to capture genetic diversity and therapy resistance phenotypes:

• PEO1 and PEO4: Isolated from the same patient before and after developing platinum resistance, both harboring the BRCA2 mutation.
• UWB1.289: Features a BRCA1 mutation.
• UWB1.289+BRCA1: A genetically engineered version with BRCA1 function restored.

Each line was cultured under both 2D and 3D (spheroid) conditions. Proteomic profiling was performed using isobaric labeling followed by high-resolution mass spectrometry, enabling quantitative comparison across conditions. The authors assessed global proteome changes, enrichment of functional pathways, and the expression of membrane-associated proteins—key for targeted therapy development. Finally, the study examined how these proteomic shifts impacted carboplatin response, with a focus on resistance-associated proteins.

Core Findings and Why They Matter

Quantitative analysis revealed broad, consistent differences in protein expression between 2D and 3D cultures:

• Upregulated in 3D spheroids: Proteins related to transmembrane transport and mitochondrial NADH:ubiquinone oxidoreductase complex I, suggesting metabolic reprogramming and altered cellular energetics.
• Downregulated in 3D spheroids: Membrane-associated proteins, notably EGFR in PEO1 cells, as well as proteins involved in DNA regulation and cell proliferation.

These findings align with previous transcriptomic reports but uniquely capture post-transcriptional and post-translational modifications, which are critical for understanding functional protein states. Importantly, 3D spheroid culture induced higher expression of proteins linked to drug resistance, including multiple NDUF family members, across all tested lines. This molecular adaptation correlated with decreased carboplatin sensitivity in 3D models, underscoring the value of spheroid systems for modeling clinically relevant resistance mechanisms. The study demonstrates that the dimensionality of in vitro cancer models is not a trivial variable, but a major determinant of both baseline protein expression and chemotherapeutic response (reference).

Comparison with Existing Internal Articles

Several recent internal resources have discussed the application and experimental optimization of carboplatin as a platinum-based DNA synthesis inhibitor in cancer research. For example, the article "Carboplatin: Platinum-Based DNA Synthesis Inhibitor Benchmarks" reviews robust preclinical evidence for carboplatin’s efficacy in ovarian and lung cancer models, emphasizing its cytotoxicity in DNA repair-deficient cells. The guide "Carboplatin (SKU A2171): Reliable Platinum-Based DNA Synthesis..." highlights the compound’s reproducibility in cell viability and cytotoxicity assays, including both 2D and 3D formats. What the present reference study adds is a molecular rationale for observed differences in drug response between 2D and 3D systems. While internal articles address workflow and assay optimization, this new proteomic evidence directly links dimensionality-driven protein expression changes to acquired carboplatin resistance. Therefore, future assay protocols and resistance modeling should incorporate 3D spheroid culture to better reflect clinical challenges.

Limitations and Transferability

While this study provides a rich proteomic dataset and clear evidence of altered carboplatin response in 3D spheroids, several limitations must be considered:

• The analysis was limited to four cell lines, albeit representing key genetic backgrounds in HGSOC.
• Proteomic profiling captures steady-state protein abundance but not dynamic changes during drug treatment or over time.
• Functional validation of candidate resistance proteins—beyond correlative expression—remains to be performed.
• Transferability to primary patient-derived models or in vivo systems requires further study, although 3D spheroids represent a significant advance over 2D monolayers.

Nevertheless, the workflow and findings are highly relevant to preclinical oncology research, especially for groups interested in platinum resistance, metabolic adaptation, and membrane protein-targeted therapeutics.

Protocol Parameters

• 3D spheroid culture initiation: Seed HGSOC cells in ultra-low attachment plates or Matrigel; optimize seeding density for compact spheroid formation (commonly 1,000–5,000 cells per spheroid).
• Proteomics sample prep: Lyse spheroids and monolayers using compatible buffers (e.g., urea-based); ensure complete dissociation for quantitative recovery.
• Isobaric labeling: TMT or iTRAQ isobaric tags are recommended for multiplexed comparison of multiple culture conditions.
• Carboplatin exposure: Apply at concentrations reflecting IC50 values for each cell line; for HGSOC, this may range from 2.2 to 116 μM as reported in the product information.
• Endpoint assays: Use cell viability, apoptosis, and proteomic analyses to assess drug response and resistance protein expression.
• Data analysis: Use pathway enrichment and protein interaction networks to interpret proteomic shifts between 2D and 3D cultures.

Research Support Resources

For investigators aiming to implement similar workflows or further dissect platinum resistance mechanisms, research-grade Carboplatin (SKU A2171) offers validated performance in both 2D and 3D in vitro models. APExBIO provides detailed handling protocols, including recommended storage at -20°C, water solubility parameters, and best practices for preparing concentrated stock solutions. Integrating carboplatin into spheroid-based workflows enables more physiologically relevant modeling of resistance, as highlighted by the current proteomic study.